Highlights
A collection of news and information related to AstraZeneca Plc published by this site and its partners.
Displaying items 1-12 of 73
» View wsbt.com items only
1
2
3
4
5
6
7
•
Next >
-
Global shares end higher as eyes turn to Fed
ReutersNEW YORK (Reuters) - Stock markets around the world edged higher on Tuesday amid signs of improving growth, even though questions about monetary policy limited gains. The Dow Jones industrial average and S&P 500 ended at all-time highs, while the...Tags: Saudi Arabia, Westpac Banking Corporation, Defense, Portugal, New Zealand
-
AstraZeneca closes in on site for new home in Cambridge
Reuters* Drugmaker eyes Cambridge Biomedical Campus - sources * Relocation centrepiece of new CEO's restructuring plan * New research centre and corporate HQ to cost some $500 mln By Ben Hirschler and Tom Bill LONDON, May 20 (Reuters) - AstraZeneca is...Tags: Research, Medical Research, Science and Technology, Entertainment Events, Nobel Prize Awards
-
Mexicana Genomma Lab distribuirá marca de antiácidos Losec
ReutersMONTERREY, 20 mayo (Reuters) - La farmacéutica mexicana Genomma Lab dijo el lunes que firmó un contrato de licencia para el uso de la marca de medicamentos de libre venta Losec, que le permitirá distribuir el popular antiácido por 99 años. Genomma... -
AstraZeneca accelerates cancer drug testing
ReutersLONDON (Reuters) - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group's new CEO delivers on a promise to accelerate its oncology programs. Britain's second-biggest drugmaker...Tags: Medical Specialization, Oncology, Ovarian Cancer, Trials, Lung Cancer
-
Cubist bid almost $1 bln for Optimer before sale process-sources
ReutersBy Jessica Toonkel NEW YORK, May 15 (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people...Tags: Thomson Corporation, Diarrhea, Cubist Pharmaceuticals Incorporated, Japan
-
Cubist bid for Optimer before sale process began: sources
ReutersNEW YORK (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters...Tags: Thomson Corporation, Diarrhea, Cubist Pharmaceuticals Incorporated, Japan
-
A taste for defensives sours prospects for European stocks
Reuters* Defensive stocks unusually leading Europe stock rally * Healthcare price/earnings ratios at five-year highs * Fund managers still favour defensives -BofA ML survey By Tricia Wright LONDON, May 14 (Reuters) - Defensive stocks such as healthcare...Tags: Finance, Chemical Industry, Mutual Funds, European Union, Novartis AG
-
RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Repeats to widen readership) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc...Tags: Chemical Industry, Conservation, European Union, European Parliament, Prices
-
U.S. spending on medicines fell for first time in 2012
Reuters(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. Overall U.S....Tags: Statins (drugs), Health Insurance Cost, Patents, Copyrights and Trademarks, Flu, Lipitor (drug)
-
XxANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
ReutersBy Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown...Tags: Chemical Industry, Conservation, European Union, European Parliament, Politics
-
REFILE-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Removes "XX" from headline) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and...Tags: Chemical Industry, Conservation, European Union, European Parliament, Prices
-
Spending on drugs falls for first time in 55 years
ReutersThe amount of money Americans spend on prescription drugs fell for the first time in 55 years, according to a report from the IMS Institute of Healthcare Informatic. The expiration of patents on widley used drugs such drugs such as Lipitor and Plaviix...Tags: Statins (drugs), Health Insurance Cost, Prescription Drugs, Plavix (drug), Pfizer Inc.
May 21, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 16, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 14, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 8, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 9, 2013
|Story| Reuters
Original site for AstraZeneca Plc topic gallery.
